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Troponin Elevation in Heart Failure
Prevalence, Mechanisms, and Clinical Implications
Robb D. Kociol, MD,* Peter S. Pang, MD,† Mihai Gheorghiade, MD,† Gregg C. Fonarow, MD,‡
Christopher M. O’Connor, MD,* G. Michael Felker, MD, MHS*
Durham, North Carolina; Chicago, Illinois; and Los Angeles, California
Circulating biomarkers have become increasingly important in diagnosing and risk stratifying patients with heart
failure (HF). While the natriuretic peptides have received much focus, there is increasing interest in the role of
circulating cardiac troponin (cTn) in detecting myocardial injury (often subclinical) in those with HF. Accumulat-
ing evidence suggests that patients with chronic and acute HF may have measurable levels of circulating cTn,
whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn as-
says are being developed, larger numbers of HF patients are found to have detectable cTn with a persistent rela-
tionship between magnitude and outcome. This knowledge improves our ability to understand the mechanism of
worsening HF, improve risk stratification, and detect potential injury related to new therapeutics in HF. As inves-
tigators begin to understand the relationship of detectable cTn to HF outcomes, as well as temporal changes in
its magnitude, and its relationship to other circulating biomarkers, more insight may be gained into the progres-
sive nature of cardiac dysfunction and the transition from chronic compensated to acute decompensated HF.
Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and im-
prove HF outcomes. (J Am Coll Cardiol 2010;56:1071–8) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.016r
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Teart failure (HF) is a growing public health problem with
ignificant morbidity, mortality, and cost to the health care
ystem (1). Circulating biomarkers, most notably the natri-
retic peptides, have emerged as central to the diagnosis and
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Manuscript received May 24, 2010, accepted June 29, 2010.isk stratification of patients with HF (2–4). In addition to
eing useful clinical tools, biomarkers may provide insights
nto underlying pathophysiology, suggesting new directions
or fundamental research or the development of new ther-
pies. Measurement of circulating cardiac troponins (cTn)
lays a fundamental role in the diagnosis and management
f the acute coronary syndromes (ACS) (5–7). In addition
o their role in ischemic heart disease, accumulating data
rovide support for the importance of cTn measurement in
oth acute and chronic HF (8–21). These observations have
road implications for prognosis, selection of therapies,
evelopment of new treatments, and understanding under-
ying mechanisms (22). For purposes of this review, we
xamined the available data on cTn in HF and the impli-
ations of these data on our understanding of this condition.
n our review, we will suggest knowledge gaps in our current
erception of the role of cTn in HF. For example, what are
he mechanisms of cTn release in HF? Does myocardial
njury play a role in disease progression or decompensation?
an monitoring of cTn help guide therapy? Can this
iomarker be used as an efficacy or safety end point in
linical trials?
iology of cTn
roponins are proteins involved in the regulation of cardiac
nd skeletal muscle contraction. The troponin complex
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tin and myosin interaction in
striated muscle. The skeletal and
cardiac isoforms of these proteins
are coded for by separate genes
and differ in structure. The car-
diac troponin complex is made of
troponin I (inhibitory), troponin C
(calcium binding), and troponin T
(tropomyosin binding) proteins.
Troponin T (TnT) is a 37 kD
protein, tightly bound to the
cardiac myofibrillar troponin-
tropomyosin complex. Troponin I
(TnI) is a 24 kD protein, which
decreases troponin C affinity for
calcium, thus inhibiting troponin-
tropomyosin interactions. Cardiac
troponin I (cTnI), in particular, is
not expressed by injured or regen-
rating skeletal muscle and is, therefore, exquisitely specific for
yocardial injury (23,24).
revalence of
etectable Troponin in HF
etectable circulating cTnI is rare in the general population
sing currently available assays (0.7%) (25). In 1997, Missov
t al. (26) were the first investigators to demonstrate
ncreased levels of circulating cTnI in patients with HF
utside the context of clinically apparent ischemia, reporting
mean cTnI of 0.74 ng/ml in 35 stable patients with
dvanced HF, using a high-sensitivity assay. When using a
tandard cTnI assay with a cut-off of 0.1 ng/ml, only 1 of 35
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BNP  B-type natriuretic
peptide
CHF  chronic heart failure
cTn  cardiac troponin
HF  heart failure
H-FABP  heart-type fatty
acid binding protein
HR  heart rate
hsTnT  high-sensitivity
troponin T
MI  myocardial infarction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ncidence of Detectable Troponin in Acute and Chronic HFTable 1 Incidence of Detectable Troponin in Acute and Chronic
First Author, Year (Ref. #) n Troponin Cut-Off V
Peacock et al., 2008 (19) 67,924 TnI and TnT TnI or TnT 0.1
Gheorghiade et al., 2005 (10) 51 TnI and TnT TnI 0.03 g/
TnT 0.01 
Del Carlo et al., 2004 (8) 62 TnT TnT 0.01 g/
La Vecchia et al., 2000 (14) 34 TnI TnI 0.3 ng/m
Metra et al., 2007 (28) 116 TnT TnT 0.01 ng/
Niizeki et al., 2007 (58) 126 TnT TnT 0.01 ng/
Parenti et al., 2008 (18) 99 TnI TnI 0.05 ng/
Perna et al., 2005 (21) 184 TnT TnT 0.1 ng/m
You et al., 2007 (41) 2,025 TnI TnI 0.5 g/l
Logeart et al., 2001 (16) 71 TnI TnI 0.026 ng
Horwich et al., 2003 (11) 238 TnI TnI 0.04 ng/
Hudson et al., 2004 (12) 136 TnT TnT 0.02 ng/
Latini et al., 2007 (15) 4,053 TnT and hsTnT TnT 0.01 ng/
hsTnT 0.00
Miller et al., 2007 (17) 190 TnT TnT 0.01 ng/
Missov et al., 1999 (27) 33 TnT TnT 0.1 ng/m
Perna et al., 2004 (20) 115 TnT TnT 0.02 ng/HF  acute heart failure; CHF  chronic heart failure; HF  heart failure; hsTnT  high-sensitivity tropoatients had a clearly positive cTn value. Similar findings
ave been reported by Latini et al. (15) from the Val-HeFT
Valsartan Heart Failure Trial). Using a standard cardiac
roponin T (cTnT) assay (detection limit  0.01 ng/ml),
0.4% of this population with chronic HF had detectable
nT. Using a high-sensitivity research assay for TnT
detection limit 0.001 ng/ml), 92% of patients had a
etectable value (15). As summarized in Table 1, multiple
tudies have now examined the prevalence of cTn eleva-
ion in patients with HF (27). As expected, the preva-
ence has varied widely as a function of the population
ype being studied, as well as the characteristics of the
tilized assay. In general, elevation of cTn has been more
arked in patients with more advanced disease, as well as
n patients with decompensated HF (10,11,28). In a
ecent analysis of the ADHERE (Acute Decompensated
eart Failure National Registry) study, 75% of patients
ospitalized with acute HF (n  67,924) had detectable
evels of cTn (cTnI 0.4 ng/ml or cTnT 0.01 g/l) (19).
hen a higher threshold for cTn elevation was utilized
cTnI of 1.0 ng/ml or cTnT of 0.1 g/l), only 6.2% of
cute HF patients had levels above these cut points (19).
nalytic Considerations
n Troponin Measurement
s with all biomarkers, understanding the role of cTn
easurements in HF requires an understanding of the
vailable assays’ limitations. Only 1 platform exists for
easurement of cTnT in the U.S. (Roche Diagnostics).
he cut-off for myocardial infarction (MI) set by the
anufacturer is 0.1 ng/ml. In contrast, there are multiple
ssays for cTnI, many with different associated cut-off values
nd sensitivities. The joint European Society of Cardiology
HF Type HF Etiology
Incidence of
Circulating Troponin
AHF Ischemic and nonischemic 6.2%
AHF Ischemic 43.5% (TnT) or
73.9% (TnI)
AHF Ischemic and nonischemic 83.9%
AHF Ischemic and nonischemic 29.0%
AHF Ischemic and nonischemic 38.0% (at baseline)
AHF Ischemic and nonischemic 26.0%
AHF Unknown 45.0%
AHF Ischemic and nonischemic 31.5%
AHF Ischemic and nonischemic 34.5%
AHF and CHF Nonischemic 27.0%
CHF Ischemic and nonischemic 49.1%
CHF Ischemic and nonischemic 24.0%
CHF Ischemic and nonischemic 10.0% (TnT) or
ml 92% (hsTnT)
CHF Ischemic and nonischemic 53.0%
CHF Ischemic and nonischemic 15.0%
CHF Ischemic and nonischemic 32.0%HF
alues
g/l
l or
g/l
l
l
ml
ml
ml
l
/ml
ml
ml
ml or
1 ng/
ml
l
mlnin T; TnI  troponin I; TnT  troponin T.
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or the Redefinition of Myocardial Infarction has defined
I as “an increased cTn, exceeding the 99th percentile of
he distribution of cTnI in the reference group for that
articular assay with an imprecision limit (coefficient of
ariation) of less than or equal to 10%” (5). However,
nalysis has shown that precision of commercially available
Tn assays are compromised at the 99th percentile reference
imit, and that there is large variation in precision between
hese assays (29). Given the relatively low concentration of
irculating cTn detected in acute and chronic HF, limita-
ions of available assays may curb the clinical information
hat can be derived from these measurements. There are,
owever, newer high-sensitivity assays that are at least an
rder of magnitude more sensitive at an imprecision limit of
0% (30,31). The development of such high-sensitivity
ssays has important implications for the clinical use and
nterpretation of cTn measurements (32).
Based on its use in the diagnosis of MI, cTn values are
ften characterized as “positive” or “negative”—a dichotomy
hat makes little sense in the context of HF. Increasingly
ensitive assays, which have demonstrated that cTn can be
etected in most patients with chronic HF (15), will
rogressively lead to the consideration of cTn as a contin-
Figure 1 Mechanism of Cardiac Troponin Release in Heart Failu
Multiple mechanisms may lead to myocyte necrosis, apoptosis, or reversible injury
all resulting in cardiac troponin release. CAD  coronary artery disease.ous variable across the spectrum of risk, similar to the
urrent usage of natriuretic peptide measurements.
echanisms of Troponin Release in HF
he mechanisms underlying cTn release in patients with
F remain speculative, and multiple mechanisms are po-
entially active in any given patient (Fig. 1). A consistently
otable finding in published studies is that cTn release
ccurs in patients with and without obstructive epicardial
oronary disease, suggesting that mechanisms other than
vert myocardial ischemia are likely to be operative. Multi-
le potential contributing mechanisms have been proposed,
ncluding subendocardial ischemia leading to myocyte ne-
rosis, cardiomyocyte damage from inflammatory cytokines
r oxidative stress, hibernating myocardium, or apoptosis
2,16,33–35). In addition, cTn may be released from in-
ured, but viable, myocardium as a result of increased
ermeability of the plasma membrane and leakage of the
ytosolic pool of cTn (20,36). Recent studies demonstrate
hat viable cardiomyocytes, without necrosis, can release
Tn as an intact protein by a stretch-related mechanism
ediated by integrins (37). Others have suggested that
ltered calcium handling, as a result of increased pre-load,
esults in activation of intracellular proteolytic enzymes that
ncreased myocyte membrane permeability,re
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Troponin Elevation in Heart Failure September 28, 2010:1071–8egrade cTn, releasing cTn fragments into the circulation,
hich may have epitopes with an affinity for the cTnI
mmunoassays (38). The common denominator of all these
rocesses, be it myocyte necrosis, apoptosis, or cTn degra-
ation or release in otherwise viable cells, would be expected
o be worsening cardiac dysfunction and progression of HF.
ecent data from a large observational study in Europe have
hown an association between low levels of circulating cTn
nd the future development of HF in completely asymp-
omatic subjects (39). These data are similar to prior
bservations with B-type natriuretic peptide (BNP) (40).
ignificance of Troponin Release in HF
ultiple studies have evaluated the association between
levated circulating cTn and adverse clinical outcomes in
arious HF populations (Table 2). Despite variations in
tudy design, patient populations, and assay characteristics,
here has been a consistent association between cTn eleva-
ion and worsened outcomes.
In patients with acute HF, the ADHERE study demon-
trated a marked increase in in-hospital mortality (8.0% vs.
.7%, p  0.001) for patients with an elevated cTn by any
linical assay at the time of hospitalization (Fig. 2) (19).
his relationship was independent of patient demographics,
rognosis and Troponin in HFTable 2 Prognosis and Troponin in HF
First Author, Year (Ref. #) n Troponin Cut-Off Values T
Peacock et al., 2008 (19) 67,924 TnI and TnT TnI or TnT 0.1 g/l A
Gheorghiade et al., 2005 (10) 51 TnI and TnT TnI 0.03 g/l or
TnT 0.01 g/l
A
Del Carlo et al., 2004 (8) 62 TnT TnT  0.01 g/l A
La Vecchia et al., 2000 (14) 34 TnI TnI 0.3 ng/ml A
Metra et al., 2007 (28) 116 TnT TnT 0.01 ng/ml A
Parenti et al., 2008 (18) 99 TnI TnI 0.05 ng/ml A
You et al., 2007 (41) 2,025 TnI TnI 0.5 g/l A
Horwich et al., 2003 (11) 238 TnI TnI 0.04 ng/ml C
Hudson et al., 2004 (12) 136 TnT TnT 0.02 ng/ml C
Latini et al., 2007 (15) 4,053 TnT and hsTnT TnT 0.01 ng/ml or
hsTnT0.001 ng/ml
C
Miller et al., 2007 (17) 190 TnT TnT 0.03 ng/ml C
NP  B-type natriuretic peptide; CI  confidence interval; cTnT  cardiac troponin T; HR  heart
eceiver-operating characteristic; RR  relative risk; other abbreviations as in Table 1.ital signs, physical examination findings, laboratory vari-bles, and BNP levels. Similarly, You et al. (41) reported
ata from the EFFECT (Enhanced Feedback for Effective
ardiac Treatment) study showing that elevated cTn (TnI
0.5 ng/ml) was associated with increased mortality even
fter multivariate adjustment, and demonstrated a dose-
esponse relationship between the magnitude of circulating
Tn and outcomes. Although data on the evolution of cTn
HF Etiology Outcome
Adjusted for
BNP or
NT-proBNP
Ischemic and nonischemic Increased in-hospital mortality No
Ischemic Baseline and peak TnI or TnT
significantly higher in patients
with worsening HF or death
during index admission
No
Ischemic and nonischemic Increased risk of 1-year death or HF
rehospitalization (best ROC at
cut-off TnT 0.02)
No
Ischemic and nonischemic 3-month mortality HR: 6.86;
95% CI: 1.32–35.4
No
Ischemic and nonischemic Mortality HR: 5.41; 4.40–6.43 Yes
Unknown RR of death for detectable vs.
undetectable 4.65; 95% CI: 1.27–17.11
No
Ischemic and nonischemic HR for death 1.49; 95% CI: 1.25–1.77 No
Ischemic and nonischemic Detectable troponin associated with
mortality (RR: 2.05;
95% CI: 1.22–3.43)
Yes
Ischemic and nonischemic Elevated troponin associated with
increased risk of death or
HF hospitalization RR: 2.7;
95% CI: 1.7–4.3; and death RR:
4.2; 95% CI: 1.8–9.5
No
Ischemic and nonischemic Mortality (cTnT) HR: 2.08; 95% CI:
1.72–2.52 (hsTnT) HR: 1.05;
95% CI: 1.04–1.07 for increments
of 0.01 ng/ml
Yes
Ischemic and nonischemic Death or cardiac transplantation
HR: 4.37; 95% CI: 2.55–7.49
Yes
TnT  high-sensitivity troponin T; NT-proBNP  N-terminal pro–B-type natriuretic peptide; ROC 
Figure 2 In-Hospital Mortality According to Troponin I Quartile
Inpatient mortality in patients with acute heart failure by troponin I quartile in
the ADHERE (Acute Decompensated Heart Failure National Registry) study.
Adapted from Peacock et al. (19).HF
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September 28, 2010:1071–8 Troponin Elevation in Heart Failuretatus in the course of acute HF hospitalization are more
imited, a few studies have evaluated serial cTn measure-
ents over time. In a small study of 62 patients with acute
F, patients with persistently elevated cTnT (0.02 ng/ml
t baseline and 7 days later) had a worse prognosis than did
atients without a persistently elevated cTn (8). Metra et al.
28) found that any elevated cTn over the course of acute
F hospitalization conferred substantially increased risk.
Similar data in ambulatory patients with HF have con-
rmed the prognostic implications of cTn release. In an
nalysis of data from the Val-HEFT study, Latini et al. (15)
ompared the prognostic implications of elevated cTn using
oth a standard cTnT assay and a high-sensitivity troponin T
hsTnT) assay. Ninety-two percent of patients had detectable
irculating cTn using the high-sensitivity assay, and hsTnT
as the most important predictor of mortality among the risk
actors analyzed. Increases in deciles of circulating cTn (after
he fourth decile) concentration incrementally increased risk
or death or mortality (15).
Miller et al. (17) examined the value of serial measure-
ents of both cTnT and BNP in chronic HF patients.
ifty-four percent of patients had a detectable cTnT at
aseline (0.01 ng/ml) and 28% of patients had a cTnT
0.03 ng/ml. The study found a highly significant associ-
tion between risk of death or cardiac transplantation and
he presence of circulating cTnT, with the subgroup con-
aining a magnitude of circulating cTnT 0.03 ng/ml as
aving the highest risk in multivariate analysis. Addition-
lly, serial measures of biomarkers revealed that changes in
Tn levels are also associated with changing levels of risk;
eclining cTnT was associated with less risk, whereas
atients with undetectable cTnT (whose levels were subse-
uently detectable) moved into a higher risk category.
nterestingly, change in BNP over time provided less robust
rognostic information in this outpatient population (17).
ore recently, Miller et al. (42) again examined serial cTnT
alues in ambulatory HF patients. In this analysis, they
haracterized patients as having no cTnT elevation who had
t least 1 cTnT elevation or persistent cTnT elevations.
hey found that more frequent elevations of cTnT were
ssociated with higher risk of death or cardiac transplanta-
ion. Furthermore, they confirmed that a greater magnitude
f cTnT (0.03 ng/ml vs. 0.01 and 0.03 ng/ml) was
ssociated with worse outcomes (42). These data strengthen
he hypothesis that worsening HF is mediated by subclinical
yocardial injury. Increased frequency and magnitude of
yocardial injury likely result in further deterioration in
entricular function and worse clinical outcomes.
In addition to prognostic information, circulating cTn
when added to other biomarker considerations), may pro-
ide insight into the transition from chronic compensated to
cute decompensated HF. Investigators have speculated
hat the transition does not necessarily represent a simple
orsening of chronic failure, but rather there is an acute
njury to the cardiac renal axis that results in decompensa-
ion. Myocardial injury in the setting of acute HF may pither be a cause or an effect of decompensation, but in
ither case, may predispose patients to subsequent progres-
ion of HF. This hypothesis is supported by the strong
elationship between hospitalization for HF and subsequent
F events (43,44). In an important recent study, Biolo et al.
45) compared BNP, cTn, and markers of ventricular
emodeling in patients with acute HF, stable HF, and
ontrol subjects. Compared with stable HF and control
atients, patients with acute HF had significantly higher
evels of circulating cTn, markers of collagen biosynthesis,
nd markers of extracellular matrix remodeling (45). These
ata suggest a link between myocardial injury and subse-
uent ventricular remodeling. After hospital discharge and
ecompensation, cTn and markers of collagen biosynthesis
evels among those admitted for acute HF declined to values
imilar to those of the chronic HF population.
cTn may not just be a marker of worsening HF, but also
mediator. In some persons, autoantibodies to cTnI de-
elop after MI. Significantly, these autoantibodies may
nterfere with the detection of circulating cTn by available
ssays (46). In mouse models, autoantibodies against cTnI
esult in a severe dilated cardiomyopathy, which is mediated
y augmentation of the L-type calcium current and result-
nt calcium overload, leading to myocyte dysfunction (47).
n further murine studies, this has been identified as a CD4
cell-mediated affect (48). The degree to which these
echanisms contribute to the development and progression
f HF in humans is unclear, but may be targets of further
nvestigation and therapeutics.
roponin Measurements in Clinical Research
espite advances in treatment, HF follows a progressive
ourse in the majority of patients, and there remains a
ubstantial need to develop new therapies for this syndrome.
ost recent drug development programs in both acute and
hronic HF have failed to conclusively demonstrate efficacy
nd safety (49,50). In acute HF in particular, the develop-
ent of new treatments has been hampered by unintended
onsequences of therapies (e.g., inotropic agents improve
emodynamics but also may cause arrhythmias or myocar-
ial ischemia). Patients with underlying ischemic heart
isease and HF may be particularly at risk for such effects.
n a subgroup analysis of the OPTIME-CHF (Outcomes of
Prospective Trial of Intravenous Milrinone for Exacerba-
ions of Chronic Heart Failure) study, there was a notable
ifferential effect of milrinone on the basis of HF etiology,
ith substantial harm to patients with underlying ischemic
eart disease (51). Adding to these observations, Gheo-
ghiade et al. (10) observed that among a cohort of patients
ith ischemic heart disease admitted to the hospital for
cute HF without evidence of ACS, 41.7% of those with
egative cTnI at baseline had detectable cTnI with serial
easurements. The release of cTnI in these patients reflects
post-admission event that may be related to the diseaserocess, administered therapies, or a combination of factors
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Troponin Elevation in Heart Failure September 28, 2010:1071–810). In the ADHERE study, cTn-elevated patients had
arkedly higher in-hospital mortality when treated with
ntravenous inotropic therapy as compared with intravenous
asodilator therapy, with an adjusted odds ratio of 4.44
95% confidence interval: 2.90 to 6.81; p  0.001) (19).
lthough currently speculative, assessments of myocardial
njury using sensitive biomarkers such as cTn may play an
mportant role in the development of new therapies, by
dentifying signals of myocyte damage earlier in the devel-
pment process (52). Finally, avoidance of myocardial injury
ay be a goal of therapy in the development of new HF
rugs, which could be incorporated into clinical trial end
oints (10). For example, in a recent phase II study of a
ovel inotropic and lusitropic compound called istaroxime,
heorghiade et al. (53) used cTnI as a secondary safety end
oint to look for evidence of treatment-induced myocardial
ecrosis.
nanswered Questions and Future Directions
hile the data summarized in the preceding text clearly
uggest the potential value of cTnI in HF risk stratification,
he clinical use of cTnI remains ill defined. Measurement of
TnI in patients hospitalized for acute HF seems warranted,
iven the desire to identify patients at high risk for adverse
utcomes, as well as to identify patients in whom ischemia
ppears to be a trigger of decompensation. The most recent
pdate of the ACC/AHA HF guidelines recommend that
Tn testing be performed in patients hospitalized with HF
Class I, Level of Evidence: C). In ambulatory patients,
vidence of ongoing cardiac injury suggests the risk of HF
rogression, particularly in patients with previously unde-
ectable cTn.
Among patients presenting with HF and an elevated
Tn, this cTn elevation may represent either myocardial
njury in the setting of acute decompensated HF or frank
CS (type 2 vs. type 1 MI based on the universal definition
f MI) (5). This represents a common conundrum for
linicians, as ACS complicated by HF mandates different
anagement than acute decompensated HF alone. This
linical problem is particularly difficult in the setting of
igns and Symptoms Differentiating AMIrom AHF in the Setting of Posi ve TroponinTable 3 Signs and Sympt ms Differentiating AMIFrom AHF in the Setting of Positive Troponin
AMI
(Type I NSTEMI) AHF
Chest pain Usually Occasionally
Shortness of breath Sometimes Usually
Detectable troponin Always Sometimes
Troponin level 1.0 ng/ml Usually Occasionally
CK-MB elevation Usually Rarely
Troponin pattern Rise and fall Persistent low level elevation
or gradual decline
BNP 100 pg/ml Sometimes Almost always
BNP 400 pg/ml Rarely Usuallyi
MI  acute myocardial infarction; CK-MB  creatine kinase–myocardial band; NSTEMI 
on–ST-segment elevation myocardial infarction; other abbreviations as in Tables 1 and 2.nderlying ischemic heart disease, the most common etiol-
gy of HF in the U.S. (54). Although some characteristics
f the clinical presentation may provide important clues
Table 3) (55), a definitive answer may require angiography
n some patients. More reliable distinction between acute
ecompensated HF and ACS with biomarkers is an impor-
ant area for further research.
A variety of important clinical questions remain unan-
wered about the role of cTn in HF. In general, studies
valuating serial measurements have been much less com-
on than studies focused on baseline values. In acute HF,
he time course of the myocardial injury relative to presen-
ation remains unclear—is myocardial injury the cause of
ecompensation, the result of hemodynamic changes lead-
ng to decompensation, or the result of therapies for acute
F? Additionally, most of the studies to date have focused
n patients with HF due to systolic dysfunction, so few data
xist on the role of cTn measurement in epidemiologically
mportant groups such as patients with HF and preserved
jection fraction. Cardiac troponin measurements may have
mportant implications in other clinical scenarios, such as in
he monitoring of potential cardiotoxicity from chemother-
peutic regimens in patients with cancer.
An additional area for further research is to better
nderstand the incremental prognostic value of cTn when
dded to models containing BNP. The fact that cTn has
rognostic significance independent of BNP has been well
stablished (11,15,56). In a study of the ADHERE study,
or every level of admission BNP, a positive value of
roponin was associated with a 2- to 3-fold increased rate of
npatient mortality (56). The ADHERE study modeled
utcomes among HF patients using clinical variables; BNP
nd high-sensitivity cTn revealed improved discrimination
y adding cTn to a model containing clinical variables and
NP, but the increase in discrimination was modest
change in c-index from 0.702 to 0.711) (15,57). More
esearch is needed in large, real-world populations to better
nderstand the incremental improvement in discrimination
nd risk reclassification by adding cTn to prognostic models.
Finally, other novel markers of cardiac injury may prove
uperior or complementary to cTn assessments. Heart-type
atty acid binding protein (H-FABP) is a small cytosolic
rotein that may be a more sensitive and reliable indicator of
ow-level myocardial damage in HF, especially when used
ogether with circulating cTn (58,59). Since H-FABP is
ytosolic, reversible myocyte injury resulting in increased
embrane permeability would cause its release, whereas
Tn is a myofibrillar protein with less in the cytosolic pool.
hus, more extensive myocyte injury must occur before
ignificant amounts of cTn are released. Additionally, cTn
nd H-FABP rates of clearance from the bloodstream are
uite different: H-FABP is cleared within 24 h, whereas
Tn is detectable for days after its release. Hence, a patient
ith an elevated cTn and normal H-FABP possibly expe-
ienced cardiac injury at some point in the recent past, but
s unlikely to be acutely experiencing injury.
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September 28, 2010:1071–8 Troponin Elevation in Heart Failureecommendations
e recommend an initial determination of cTn for patients
resenting to the hospital with acute HF. Troponin assess-
ent can be used for immediate risk stratification and may
lso suggest ACS as the underlying etiology, depending on
ther presenting features. In patients with initially elevated
Tn levels, a repeat cTn measurement within 6 to 12 h in
atients can help determine whether or not the kinetics of
Tn change are more consistent with either ACS or acute
ecompensated HF. In ambulatory patients with HF, cTn
easurement is a reasonable prognostic indicator. Persis-
ently elevated cTn values in chronic HF patients should
ead to consideration of more intensive medical therapy, as
ell as an evaluation for ischemic heart disease (if not
lready performed).
onclusions
ardiac troponin represents markers of myocardial injury
hat are detected in a significant portion of patients with
cute and chronic HF. The incidence of detection depends
n the sensitivity of the assay used. At all concentrations,
he presence of circulating, detectable, cTn appear to have
mportant prognostic significance. Cardiac troponin levels
re associated with an increased risk of morbidity and
ortality in both acute and chronic HF, providing incre-
ental prognostic information to standard clinical assess-
ent and other laboratory variables. As the sensitivity of
ssays improves, cTn will increasingly be seen as a contin-
ous (rather than dichotomous) variable. Preliminary stud-
es suggest cTn may help assess response to HF therapy and
dentify patients for whom more intensive monitoring and
anagement may be needed. The mechanisms of cardiac
njury in acute and chronic HF resulting in cTn release
eeds to be clearly elucidated. Many unanswered questions
oint toward the need to accumulate more prospective,
igh-quality data on the mechanisms, timing, and clinical
mplications of cTn release in HF.
cknowledgment
he authors would like to thank Erin LoFrese for her
ditorial contributions to this manuscript.
eprint requests and correspondence: Dr. G. Michael Felker,
uke Clinical Research Institute, 2400 Pratt Street, Room 0311,
errace Level, Durham, North Carolina 27705. E-mail: michael.
elker@duke.edu.
EFERENCES
1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke
statistics—2008 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation
2008;117:e25–146.2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:
2148–59.3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
4. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic
peptide and norepinephrine over time and mortality and morbidity in
the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:
1278–83.
5. Thygesen K, Alpert JS, White HD, et al. Universal definition of
myocardial infarction. Circulation 2007;116:2634–53.
6. Kushner FG, Hand M, Smith SC Jr., et al. 2009 focused updates:
ACC/AHA guidelines for the management of patients with ST-
elevation myocardial infarction (updating the 2004 guideline and 2007
focused update) and ACC/AHA/SCAI guidelines on percutaneous
coronary intervention (updating the 2005 guideline and 2007 focused
update): a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol 2009;54:2205–41.
7. Pollack CV Jr., Braunwald E. 2007 update to the ACC/AHA
guidelines for the management of patients with unstable angina and
non-ST-segment elevation myocardial infarction: implications for
emergency department practice. Ann Emerg Med 2008;51:591–606.
8. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, Latorre Mdo
R, Ramires JA. Serial measure of cardiac troponin T levels for
prediction of clinical events in decompensated heart failure. J Card Fail
2004;10:43–8.
9. Gattis WA, O’Connor CM, Hasselblad V, Adams KF Jr., Kobrin I,
Gheorghiade M. Usefulness of an elevated troponin-I in predicting
clinical events in patients admitted with acute heart failure and acute
coronary syndrome (from the RITZ-4 trial). Am J Cardiol 2004;93:
1436–7.
0. Gheorghiade M, Gattis Stough W, Adams KF Jr., Jaffe AS, Hassel-
blad V, O’Connor CM. The Pilot Randomized Study of Nesiritide
Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J
Cardiol 2005;96:18G–25G.
1. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin
I is associated with impaired hemodynamics, progressive left ventric-
ular dysfunction, and increased mortality rates in advanced heart
failure. Circulation 2003;108:833–8.
2. Hudson MP, O’Connor CM, Gattis WA, et al. Implications of
elevated cardiac troponin T in ambulatory patients with heart failure:
a prospective analysis. Am Heart J 2004;147:546–52.
3. Kuwabara Y, Sato Y, Miyamoto T, et al. Persistently increased serum
concentrations of cardiac troponin in patients with acutely decompen-
sated heart failure are predictive of adverse outcomes. Circ J 2007;71:
1047–51.
4. La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as
diagnostic and prognostic marker in severe heart failure. J Heart Lung
Transplant 2000;19:644–52.
5. Latini R, Masson S, Anand IS, et al. Prognostic value of very low
plasma concentrations of troponin T in patients with stable chronic
heart failure. Circulation 2007;116:1242–9.
6. Logeart D, Beyne P, Cusson C, et al. Evidence of cardiac myolysis in
severe nonischemic heart failure and the potential role of increased wall
strain. Am Heart J 2001;141:247–53.
7. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker
measurements in ambulatory patients with chronic heart failure: the
importance of change over time. Circulation 2007;116:249–57.
8. Parenti N, Bartolacci S, Carle F, Angelo F. Cardiac troponin I as
prognostic marker in heart failure patients discharged from emergency
department. Intern Emerg Med 2008;3:43–7.
9. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and
outcome in acute heart failure. N Engl J Med 2008;358:2117–26.
0. Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in
stable severe heart failure: value of cardiac troponin T monitoring for
high-risk patient identification. Circulation 2004;110:2376–82.
1. Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardial
damage detected by troponin T is a powerful predictor of long-term
prognosis in patients with acute decompensated heart failure. Int
J Cardiol 2005;99:253–61.
2. Del Carlo CH, O’Connor CM. Cardiac troponins in congestive heart
failure. Am Heart J 1999;138:646–53.
3. Adams JE III, Bodor GS, Davila-Roman VG, et al. Cardiac troponin
I. A marker with high specificity for cardiac injury. Circulation
1993;88:101–6.
22
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
1078 Kociol et al. JACC Vol. 56, No. 14, 2010
Troponin Elevation in Heart Failure September 28, 2010:1071–84. Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS. Cardiac
troponin-I is not expressed in fetal and healthy or diseased adult
human skeletal muscle tissue. Clin Chem 1995;41:1710–5.
5. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and
determinants of troponin T elevation in the general population.
Circulation 2006;113:1958–65.
6. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe
congestive heart failure. Circulation 1997;96:2953–8.
7. Missov E, Mair J. A novel biochemical approach to congestive heart
failure: cardiac troponin T. Am Heart J 1999;139:95–9.
8. Metra M, Nodari S, Parrinello G, et al. The role of plasma
biomarkers in acute heart failure. Serial changes and independent
prognostic value of NT-proBNP and cardiac troponin-T. Eur
J Heart Fail 2007;9:776 – 86.
9. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for
cardiac troponin assays at low-range concentrations. Clin Chem
2004;50:327–32.
0. Wu AH, Agee SJ, Lu QA, Todd J, Jaffe AS. Specificity of a
high-sensitivity cardiac troponin I assay using single-molecule-
counting technology. Clin Chem 2009;55:196–8.
1. Morrow DA, Antman EM. Evaluation of high-sensitivity assays for
cardiac troponin. Clin Chem 2009;55:5–8.
2. Rosenbaum LS, Januzzi JL. Moving troponin testing into the 21st
century: will greater sensitivity be met with greater sensibility? Car-
diovasc Hematol Disord Drug Targets 2008;8:118–26.
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med 1990;323:236–41.
4. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in
end-stage heart failure. N Engl J Med 1996;335:1182–9.
5. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human
heart. N Engl J Med 1997;336:1131–41.
6. Sato Y, Kita T, Takatsu Y, Kimura T. Biochemical markers of
myocyte injury in heart failure. Heart 2004;90:1110–13.
7. Hessel MH, Atsma DE, van der Valk EJ, Bax WH, Schalij MJ, van
der Laarse A. Release of cardiac troponin I from viable cardiomyocytes
is mediated by integrin stimulation. Pflugers Arch 2008;455:979–86.
8. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM Jr. Preload
induces troponin I degradation independently of myocardial ischemia.
Circulation 2001;103:2035–7.
9. Sundstrom J, Ingelsson E, Berglund L, et al. Cardiac troponin-I and
risk of heart failure: a community-based cohort study. Eur Heart J
2009;30:773–81.
0. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels
and the risk of cardiovascular events and death. N Engl J Med
2004;350:655–63.
1. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation between
cardiac troponin I and mortality in acute decompensated heart failure.
Am Heart J 2007;153:462–70.
2. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of
serial changes in cardiac troponin T concentrations and outcome in
ambulatory patients with chronic heart failure. J Am Coll Cardiol
2009;54:1715–21.
3. O’Connor CM, Abraham WT, Albert NM, et al. Predictors of
mortality after discharge in patients hospitalized with heart failure: an
analysis from the Organized Program to Initiate Lifesaving Treatment
in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am
Heart J 2008;156:662–73. K4. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of
in-hospital mortality in patients hospitalized for heart failure: insights
from the Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am
Coll Cardiol 2008;52:347–56.
5. Biolo A, Fisch M, Balog J, et al. Episodes of acute heart failure
syndrome are associated with increased levels of troponin and extra-
cellular matrix markers. Circ Heart Fail 2010;3:44–50.
6. Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac
troponins. N Engl J Med 2005;352:98–100.
7. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac
troponin I are responsible for dilated cardiomyopathy in PD-1-
deficient mice. Nat Med 2003;9:1477–83.
8. Kaya Z, Goser S, Buss SJ, et al. Identification of cardiac troponin I
sequence motifs leading to heart failure by induction of myocardial
inflammation and fibrosis. Circulation 2008;118:2063–72.
9. Gheorghiade M, Adams KF, Cleland JG, et al. Phase III clinical trial
end points in acute heart failure syndromes: a virtual roundtable with
the Acute Heart Failure Syndromes International Working Group.
Am Heart J 2009;157:957–70.
0. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a
crossroad: are there limits to the neurohormonal model? J Am Coll
Cardiol 2003;41:1606–10.
1. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and
response to milrinone in decompensated heart failure: results from the
OPTIME-CHF study. J Am Coll Cardiol 2003;41:997–1003.
2. Berridge BR, Pettit S, Walker DB, et al. A translational approach to
detecting drug-induced cardiac injury with cardiac troponins: consen-
sus and recommendations from the Cardiac Troponins Biomarker
Working Group of the Health and Environmental Sciences Institute.
Am Heart J 2009;158:21–9.
3. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic,
echocardiographic, and neurohormonal effects of istaroxime, a novel
intravenous inotropic and lusitropic agent: a randomized controlled
trial in patients hospitalized with heart failure. J Am Coll Cardiol
2008;51:2276–85.
4. The SOLVD Investigators. Studies of left ventricular dysfunction
(SOLVD)—rationale, design and methods: two trials that evaluate the
effect of enalapril in patients with reduced ejection fraction. Am J
Cardiol 1990;66:315–22.
5. Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C.
Acute coronary syndrome vs nonspecific troponin elevation: clinical
predictors and survival analysis. Arch Intern Med 2007;167:276–81.
6. Fonarow G, Peacock WF, Horwich TB, et al. Usefulness of B-type
natriuretic peptide and cardiac troponin levels to predict in-hospital
mortality from ADHERE. Am J Cardiol 2008;101:231–7.
7. Wang TJ. Significance of circulating troponins in heart failure: if these
walls could talk. Circulation 2007;116:1217–20.
8. Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding
protein is more sensitive than troponin T to detect the ongoing
myocardial damage in chronic heart failure patients. J Card Fail
2007;13:120–7.
9. Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum
concentration of heart-type fatty acid-binding protein predicts adverse
clinical outcomes in patients with chronic heart failure. Circ J
2008;72:109–14.ey Words: biomarkers y heart failure y outcomes.
